Man burned in Fort Lauderdale boat fire on Memorial Day weekend has died, loved ones say
Joshua Fifi, 28, suffered third-degree burns over 70% of his body. The father of four spent four days in the hospital before his death. The announcement was made in a "GoFundMe" fundraiser.
Fifi was one of 14 people onboard the aboard a 39-foot Sea Ray boat that caught fire after Fort Lauderdale Fire Rescue said fuel vapors somehow ignited. The source of the vapors has not yet been determined. Eleven were hospitalized, including two children. Ten patients, including the boys, were taken to the burn unit at Jackson Memorial Hospital.
Grandmother worried for her grandsons
Sylvia Rivera spoke with CBS News Miami about her 5-year-old and 7-year-old grandsons, who remain in serious condition.
Rivera said the 7-year-old has burns over 80% of his body, while the 5-year-old has burns over 40%.
The boys' mother, Cassandra Rivera, posted a message on Facebook thanking people for their prayers. She said there is a "long road of recovery" ahead and she is facing multiple surgeries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Man Is 'Tired of Dealing with' Picky Family Members After His Birthday Dinner Plans Lead to 'Hostile' Interaction
The man says he's spent years adjusting every meal around his dad's wife and her son's extreme dietary needsNEED TO KNOW A man chose a restaurant he liked for his birthday dinner, upsetting his dad's wife and her son who have restrictive diets The family demanded he move the dinner out of state to suit their preferences — he refused The man is now facing backlash for holding firm, but says he no longer considers them real familyA man seeks support from the Reddit community for advice following a tense birthday dinner that reignites years of unresolved family tensions. In his post, the 22-year-old explains how choosing a restaurant for his birthday sparked backlash from his father's wife, Kathleen, and her son, Benjamin. 'My dad got married to Kathleen when I was 15,' the poster shared, noting that Kathleen has two children of her own, one of whom he has never met. The one he does know — Benjamin, now 18 — has multiple allergies and an extremely limited diet, which has long dictated the family's eating habits. 'Benjamin is allergic to peanuts and shellfish,' the man wrote, adding that the allergy is just part of the challenge. 'On top of that him and Kathleen are very picky eaters.' He recalled how meals were always restricted when he lived with them. 'His diet when I lived there consisted of pizza, fries and burgers and beef and cheese tacos,' he shared. 'He didn't eat fruits or vegetables. He didn't eat any meat except for beef.' Kathleen, too, has a long list of dislikes. 'I can't remember all the stuff she wouldn't eat but it included any kind of fish, any kind of potato, rice, pasta, bread and stuff like that," the Redditor wrote, noting that this limited nearly every family meal to just a few fast food spots. Ordering takeout or dining out as a family became an exhausting routine. 'The food was never great but could've been worse,' he added. 'I think the part that sucked was every time we ordered out for my birthday or went out for my birthday it was one of the two places we had.' Even simple options like tacos were difficult to manage. 'A taco place was out unless they'd remove all veggies and extras except for the meat and cheese,' he recalled. 'And some places still put 'gross s---' to quote Benjamin on them when they did seemingly comply.' As he grew older, he began skipping their 'family meals,' tired of being forced into their limited choices. 'Anytime still they want to do a family meal out they expect us all to go to their chosen fast food places that work for Benjamin and Kathleen,' he explained. 'And I'm tired of dealing with them.' This year, for his birthday, he decided to do things differently. 'A few weeks ago I had a birthday dinner with my girlfriend and some family and friends,' he wrote. 'Dad wanted to come and he expected Kathleen and Benjamin to be invited too.' The poster made it clear that they were welcome—as long as they were willing to eat at the restaurant he picked. 'I told him that was okay if they'd eat where I had chosen,' he shared. But soon after, he was met with resistance. 'I got an email from Kathleen and calls from dad where I was told my restaurant of choice did not meet the needs and requirements of Benjamin and Kathleen," the Redditor explained. The pair even suggested that he and his guests travel out of state for a more suitable dining option for them. His response was firm. 'My answer was no and I told dad he could still come but I was not changing where I have MY birthday dinner," he wrote. However, Kathleen did not take the refusal lightly. 'Kathleen sent another email asking why I was being so hostile like her daughter and I should care about my family's health and interests,' he noted. The message struck a nerve, especially since he's never even met her daughter. Tensions rose further when his dad and Kathleen learned that other members of his dad's family traveled to join the birthday celebration. 'Dad and Kathleen were more upset to learn some of dad's side flew out to join us for dinner when they typically won't accept plans from them to eat out," the original poster continued. Now, he said, he's facing even more backlash for simply choosing a restaurant he liked. 'So now I'm facing more of their anger for my choice of restaurant,' he shared. But as he turns to Reddit to ask if he's in the wrong, the support he receives is clear. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. 'NTA,' one commenter wrote. 'It's your birthday. And it sounds like she is fully just your dad's wife. Not any kind of stepmom.' In response, the original poster shared what seems to be the heart of the matter. 'That sums it up,' he wrote. 'I don't consider either of them any kind of real family. Only people my dad chose as his family.' Read the original article on People Solve the daily Crossword
Yahoo
19 minutes ago
- Yahoo
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase 1/2 study nearing completion of enrollment; planning underway for a global Phase 3 confirmatory study On track to submit regulatory applications in 2025 to begin clinical testing of one to two additional TransportVehicleTM (TV)-enabled programs Preclinical research on ATV:Abeta program for Alzheimer's disease published in the journal Science SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights. 'The FDA's priority review of our BLA for tividenofusp alfa and alignment on an accelerated approval path for DNL126 are key milestones highlighting the potential of our Transport Vehicle (TV) platform to catalyze a new class of blood-brain barrier-crossing therapeutics,' said Ryan Watts, Ph.D., CEO of Denali Therapeutics. 'With launch readiness in motion and a growing portfolio of TV-enabled enzyme, antibody, and oligonucleotide programs, Denali is poised to deliver meaningful treatments for people living with lysosomal, neurodegenerative, and other serious diseases.' Second Quarter 2025 and Recent Program Updates CLINICAL PROGRAMS Tividenofusp alfa (DNL310, ETV:IDS) for Hunter syndrome (MPS II) In July 2025, Denali announced that the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for tividenofusp alfa for priority review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of January 5, 2026. The BLA seeks accelerated approval based on a data package including results from the Phase 1/2 study in individuals with Hunter syndrome. Tividenofusp alfa is an investigational, next-generation enzyme replacement therapy designed to cross the blood-brain barrier (BBB) and deliver the iduronate-2-sulfatase (IDS) enzyme throughout the body and brain. The FDA previously granted tividenofusp alfa Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Denali continues to prepare for commercial launch and is conducting the Phase 2/3 COMPASS study to support global regulatory submissions. DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA) Today, Denali announced that it has reached alignment with the FDA's Center for Drug Evaluation and Research (CDER) that cerebrospinal fluid heparan sulfate (CSF HS) may be considered a reasonably likely surrogate endpoint to predict clinical benefit and may therefore be used to support accelerated approval of DNL126 for MPS IIIA. Additional 49-week data from the ongoing open-label Phase 1/2 study are consistent with previously announced 25-week data, demonstrating a significant reduction in CSF HS from baseline, including normalization, and a safety profile that supports continued development. Enrollment in the Phase 1/2 study is nearly complete, and planning is underway for a confirmatory global Phase 3 study. TAK-594/DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia Denali and Takeda continue their collaboration to develop DNL593, an investigational therapeutic designed to deliver progranulin across the BBB for the treatment of granulin (GRN) mutation-associated frontotemporal dementia (FTD-GRN). A Phase 1/2 study is ongoing. BIIB122/DNL151 (small molecule LRRK2 inhibitor) for the treatment of Parkinson's disease (PD) Denali and Biogen are co-developing LRRK2 inhibitors for Parkinson's disease. In May 2025, Biogen announced that the Phase 2b LUMA study of BIIB122 completed enrollment, with a readout expected in 2026. Denali is also conducting the Phase 2a BEACON study focused on LRRK2-associated PD. IND-ENABLING STAGE PROGRAMS Denali expects to submit regulatory applications to begin clinical testing of one to two TV-enabled programs each year over the next three years across its Enzyme TV (ETV), Antibody TV (ATV), and Oligonucleotide TV (OTV) franchises. The most advanced programs include: DNL952 (ETV:GAA) for Pompe disease; DNL111 (ETV:GCase) for Parkinson's/Gaucher disease; DNL622 (ETV:IDUA) for MPS I; DNL921 (ATV:Abeta) for Alzheimer's disease; DNL628 (OTV:MAPT) for Alzheimer's disease; and DNL422 (OTV:SNCA) for Parkinson's disease. Denali announced publication of preclinical data on ATV:Abeta in the August 7, 2025, issue of the journal Science. The research demonstrated that delivering an anti-amyloid beta antibody across the BBB using Denali's TV platform improved brain distribution and reduced the risk of amyloid-related imaging abnormality (ARIA) in a mouse model of Alzheimer's disease, compared to conventional antibody treatment. The findings suggest that TV platform-enabled brain delivery of immunotherapy bypasses amyloid-laden large vessels by traveling through smaller capillaries, offering a potential strategy to mitigate ARIA risk seen with first-generation anti-amyloid therapies. The Science article can be accessed here. Participation in Upcoming Investor Conferences Cantor Global Healthcare Conference 2025, September 3 - 5 (New York City) Morgan Stanley 23rd Annual Global Healthcare Conference, September 8 - 10 (New York City) Baird 2025 Global Healthcare Conference, September 9 - 10 (New York City) H.C. Wainwright 27th Annual Global Investment Conference, September 8 - 10 (New York City) Deutsche Bank BioPharm Corporate Day, September 18 - 19 (Austria) Stifel 2025 Healthcare Conference, November 11 - 13 (New York City) Jefferies Global Healthcare Conference, November 17 - 20 (London) Second Quarter 2025 Financial Results Net loss was $124.1 million for the quarter ended June 30, 2025, compared to net loss of $99.0 million for the quarter ended June 30, 2024. Total research and development expenses were $102.7 million for the quarter ended June 30, 2025, compared to $91.4 million for the quarter ended June 30, 2024. The increase of approximately $11.3 million was attributable to an increase of $7.3 million in TV program external research and development expenses, primarily driven by increased spend on multiple preclinical programs, and increases of $7.6 million and $6.2 million in other research and development expenses and personnel-related expenses, respectively, both driven by the commencement of operations at Denali's large molecule manufacturing facility in Salt Lake City, Utah. These increases were partially offset by a $9.8 million decrease in small molecule programs, primarily due to the winding down of activities related to the Phase 2/3 HEALEY ALS Platform Trial. General and administrative expenses were $32.3 million for the quarter ended June 30, 2025, compared to $25.2 million for the quarter ended June 30, 2024. The increase of $7.1 million was primarily driven by activities related to preparations for a potential commercial launch for tividenofusp alfa. Cash, cash equivalents, and marketable securities were approximately $977.4 million as of June 30, 2025. About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics and commercial potential; statements made by Denali's Chief Executive Officer; plans, timelines, and expectations relating to DNL310, including the PDUFA target action date and the timing, likelihood of, and scope of regulatory approval, the ongoing global Phase 2/3 COMPASS study and the likelihood of global approvals, and planned commercial launch; plans, timelines, and expectations related to DNL126, including enrollment in the ongoing Phase 1/2 study, plans regarding the confirmatory global Phase 3 study, planned engagement with the FDA, and the likelihood and scope of regulatory approvals; plans regarding DNL593 and the ongoing Phase 1/2 study; plans, timelines, and expectations regarding DNL151, including with respect to the ongoing Phase 2b LUMA study and the timing and likelihood of readout, and the ongoing Phase 2a BEACON study; plans and expectations for Denali's preclinical programs, including the timing of advancement to clinical studies; the findings from Denali's recent Science publication and their therapeutic potential regarding ARIA risk; Denali's participation in upcoming investor conferences; and Denali's future operating expenses and anticipated cash runway. All drugs currently being developed by Denali are investigational and have not received regulatory approval for any indication. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to: the impact of adverse economic conditions, tariffs, and inflation on Denali's business and operations; the occurrence of any event, change, or other circumstance that could give rise to the termination of Denali's agreements with Sanofi, Takeda, Biogen, or other collaborators; Denali's transition to a late-stage clinical drug development company; Denali's and its collaborators' ability to complete the development and, if approved, commercialization of its product candidates; Denali's and its collaborators' ability to enroll patients in its ongoing and future clinical trials; Denali's reliance on third parties for the manufacture and supply of its product candidates for clinical trials; Denali's dependence on successful development of its blood-brain barrier platform technology and its programs and product candidates; Denali's and its collaborators' ability to conduct or complete clinical trials on expected timelines; the risk that preclinical profiles of Denali's product candidates may not translate in clinical trials; the potential for clinical trials to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the uncertainty that product candidates will receive regulatory approval necessary to be commercialized; Denali's ability to continue to create a pipeline of product candidates or commercialize products; developments relating to Denali's competitors and its industry, including competing product candidates and therapies; Denali's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Denali's strategic plans for its business, product candidates, and blood-brain barrier platform technology; Denali's ability to obtain additional capital to finance its operations, as needed; Denali's ability to accurately forecast future financial results and hedge against financial risk in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual Report and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and May 6, 2025, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results, or to make changes in Denali's expectations, except as required by law. Denali Therapeutics Consolidated Statements of Operations(Unaudited)(In thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 102,696 $ 91,399 218,923 198,415 General and administrative 32,267 25,194 61,620 50,430 Total operating expenses 134,963 116,593 280,543 248,845 Gain from divestiture of small molecule programs — — — 14,537 Loss from operations (134,963 ) (116,593 ) (280,543 ) (234,308 ) Interest and other income, net 10,844 17,567 23,454 33,480 Net loss $ (124,119 ) $ (99,026 ) $ (257,089 ) $ (200,828 ) Net loss per share, basic and diluted $ (0.72 ) $ (0.59 ) $ (1.50 ) $ (1.26 ) Weighted average number of shares outstanding, basic and diluted 171,449,847 168,831,329 171,336,568 159,117,759 Denali Therapeutics Consolidated Balance Sheets(Unaudited)(In thousands) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 141,207 $ 174,960 Short-term marketable securities 757,745 657,371 Prepaid expenses and other current assets 35,754 32,105 Total current assets 934,706 864,436 Long-term marketable securities 78,463 359,373 Property and equipment, net 58,717 55,236 Finance lease right-of-use asset 50,363 47,533 Operating lease right-of-use asset 21,022 22,861 Other non-current assets 22,970 24,741 Total assets $ 1,166,241 $ 1,374,180 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 10,844 $ 11,137 Accrued compensation 12,068 24,728 Accrued clinical and other research & development costs 23,379 22,822 Accrued manufacturing costs 9,028 12,779 Operating lease liability, current 8,871 8,308 Deferred research and development funding liability, current 19,861 14,129 Other accrued costs and current liabilities 7,006 8,305 Total current liabilities 91,057 102,208 Operating lease liability, less current portion 32,110 36,673 Finance lease liability, less current portion 5,577 5,615 Deferred research funding and development liability, less current portion 10,444 — Total liabilities 139,188 144,496 Total stockholders' equity 1,027,053 1,229,684 Total liabilities and stockholders' equity $ 1,166,241 $ 1,374,180 Investor Contact:Laura Hansen, Media Contact:Erin Pattonepatton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
FACT FOCUS: Trump exaggerates, misstates facts on Washington crime
WASHINGTON (AP) — President Donald Trump said Monday that his administration will take over policing the nation's capital city in what the Republican said is an effort to bring down rising crime rates in Washington, D.C. But Trump exaggerated or misstated many of the facts surrounding public safety in Washington, where the crime rate has fallen in recent years, while leaving out much of the context. Here's a closer look at the facts: Statistics rebut Trump's claims about violence crime in Washington TRUMP: 'It's getting worse, not getting better. It's getting worse.' THE FACTS: Statistics published by Washington's Metropolitan Police contradict the president and show violent crime has dropped in Washington since a post-Pandemic peak in 2023. According to the data, homicides, robberies and burglaries are down this year when compared with this time in 2024. Overall, violent crime is down 26% compared with this time a year ago. A recent Department of Justice report shows that violent crime is down 35% since 2023, returning to the previous trend of decreasing crime that puts the district's violent crime rate at its lowest in 30 years. That report shows that when compared to 2023 numbers, homicides are down 32%, armed carjackings are down 53% and assaults with a dangerous weapon are down 27%. The city's statistics have come into question, however, after authorities opened an investigation into allegations that officials altered some of the data to make it look better. But Mayor Muriel Bowser stands by the data and said Trump's portrait of lawlessness is inaccurate. 'We are not experiencing a spike in crime," Bowser said on MSNBC Sunday. "In fact, we're watching our crime numbers go down.' Murders in 2023 in Washington were high, but not the highest ever TRUMP: "Murders in 2023 reached the highest rate, probably ever. They say 25 years, but they don't know what that means because it just goes back 25 years." THE FACTS: In 2023, the District of Columbia recorded 274 murders in a city of about 700,000, its highest number in 20 years. But the city's own crime statistics from the 1970s, 80s and 90s, when the population was smaller, show much higher numbers of homicides. In 1990, for instance, the city reported 498 homicides. The next year saw 509, and 460 in 1992. Decades of statistics on crime in the city is available online. Washington murder rate compared to international capitals TRUMP: 'The murder rate in Washington today is higher than that of Bogota, Colombia, Mexico City. Some of the places that you hear about as being the worst places on Earth, much higher. This is much higher." THE FACTS: It's true, but Trump isn't telling the whole story. Washington does have a higher homicide rate than many other global cities, including some that have historically been considered unsafe by many Americans. But Trump is leaving out important context: the U.S. in general sees higher violent crime rates than many other countries. While Washington is one of America's most dangerous big cities, others have higher crime rates. Trump blames cashless bail for crime without evidence TRUMP : "This dire public safety crisis stems from a public safety crisis that is directly from the abject failures of the city's local leadership. The radical left City Council adopted no cash bail. By the way, every place in the country where you have no cash bail is a disaster." THE FACTS: Data has not determined the impact of cashless bail on crime rates. Studies, many of which focus on recidivism of defendants rather than crime rates, have shown mixed results. A 2024 report published by the Brennan Center for Justice saw 'no statistically significant relationship' between bail reform and crime rates. The nonprofit looked at crime rate data from 2015 through 2021 for 33 cities across the U.S., 22 of which had instituted some type of bail reform. Researchers used a statistical method to determine if crime rates had diverged in those with reforms and those without. Ames Grawert, the report's co-author and senior counsel in the Brennan Center's Justice Program, said this conclusion 'holds true for trends in crime overall or specifically violent crime.' Similarly, a 2023 paper published in the American Economic Journal found no evidence that cash bail helps ensure defendants will show up in court or prevents crime among those who are released while awaiting trial. 'I don't know of any valid studies corroborating the President's claim and would love to know what the Administration offers in support,' Kellen Funk, a professor at Columbia Law School who studies pretrial procedure and bail bonding, told The Associated Press in a July 25 fact check. 'In my professional judgment I'd call the claim demonstrably false and inflammatory.' The Trump administration has cited a 2022 report from the district attorney's office in Yolo County, California, that looked at how a temporary cashless bail system implemented across the state to prevent COVID-19 outbreaks in courts and jails impacted recidivism. It found that out of 595 individuals released between April 2020 and May 2021 under this system, 70.6% were arrested again after they were released. Funk, contacted Monday, noted that Washington D.C. reformed its cash bail system in the 1990s. 'What the President is declaring to be an 'emergency' is a system that has functioned much better than cash-based bail systems for nearly thirty years now, including during the recent historic lows in reported crime in the District,' he said, adding that 'the D.C. bail system has served as a model for bipartisan bail reform efforts in New Jersey and New Mexico over the past decade.' ___ Associated Press writer Melissa Goldin in New York contributed reporting. ___ Find AP Fact Checks here:
